Molecular imaging and radionuclide therapy · 2026
Prognostic Value of Primary Tumor and Immune Organ Metabolic Parameters Derived from Pretreatment 18F-FDG PET/CT in Gastric Adenocarcinoma: A Retrospective Survival Analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Özçevik Halim, Öner Tamam Müge, Acar Tayyar Merve Nur
Аннотация
OBJECTIVE: To investigate the association of primary tumor volume-based parameters and immune organ (liver, spleen, bone marrow) metabolic parameters and their derived ratios [spleen-to-liver ratio (SLR), bone marrow-to-liver ratio (BLR), spleen-to-bone marrow ratio (SBR)], measured on pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), with overall survival in gastric adenocarcinoma.
METHODS: 127 patients with histopathologically confirmed gastric adenocarcinoma who underwent pretreatment 18F-FDG PET/CT were retrospectively evaluated. Maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, total lesion glycolysis (TLG) and immune-organ SUVs were measured and the ratios calculated. Survival analyses used the Kaplan-Meier method, log-rank test, and Cox regression.
RESULTS: There were 91 death events (71.7%); the Kaplan-Meier median overall survival was 16.56 months, with 1-, 3-, and 5-year survival rates of 58.3%, 33.1%, and 28.1%, respectively. No significant independent association with overall survival was demonstrated for any of the primary-tumor or immune-organ PET/CT parameters; the SBR was lower in deceased patients (p=0.041) and showed a non-significant protective trend at the univariate level [hazard ratio (HR)=0.802 per 1 standard deviation (SD); 95% confidence interval (CI) 0.621-1.038; p=0.093)], which was not supported by cut-off-based or multivariable analyses. In the primary multivariable model, distant metastasis independently increased the hazard of death (HR=1.798; 95% CI 1.187-2.723; p=0.006), whereas TLG SLR, and BLR showed no independent significance. In the stage-adjusted model, advanced stage remained independently associated with OS (HR=4.403; p=0.001).
CONCLUSION: In this gastric adenocarcinoma cohort with a high proportion of advanced-stage disease, no independent association with overall survival was demonstrated for any of the evaluated tumor- or immune-organ PET/CT parameters; established clinicopathological factors showed stronger prognostic associations than the PET-derived parameters. The prognostic role of immune organ metabolism in gastric cancer should be evaluated in large prospective studies.
METHODS: 127 patients with histopathologically confirmed gastric adenocarcinoma who underwent pretreatment 18F-FDG PET/CT were retrospectively evaluated. Maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, total lesion glycolysis (TLG) and immune-organ SUVs were measured and the ratios calculated. Survival analyses used the Kaplan-Meier method, log-rank test, and Cox regression.
RESULTS: There were 91 death events (71.7%); the Kaplan-Meier median overall survival was 16.56 months, with 1-, 3-, and 5-year survival rates of 58.3%, 33.1%, and 28.1%, respectively. No significant independent association with overall survival was demonstrated for any of the primary-tumor or immune-organ PET/CT parameters; the SBR was lower in deceased patients (p=0.041) and showed a non-significant protective trend at the univariate level [hazard ratio (HR)=0.802 per 1 standard deviation (SD); 95% confidence interval (CI) 0.621-1.038; p=0.093)], which was not supported by cut-off-based or multivariable analyses. In the primary multivariable model, distant metastasis independently increased the hazard of death (HR=1.798; 95% CI 1.187-2.723; p=0.006), whereas TLG SLR, and BLR showed no independent significance. In the stage-adjusted model, advanced stage remained independently associated with OS (HR=4.403; p=0.001).
CONCLUSION: In this gastric adenocarcinoma cohort with a high proportion of advanced-stage disease, no independent association with overall survival was demonstrated for any of the evaluated tumor- or immune-organ PET/CT parameters; established clinicopathological factors showed stronger prognostic associations than the PET-derived parameters. The prognostic role of immune organ metabolism in gastric cancer should be evaluated in large prospective studies.